Fate of Avastin in early-stage cancer uncertain after second Phase III failure in colon cancer

Roche is facing further disappointment with its top selling drug, Avastin (bevacizumab) – which is so far approved for advanced/metastatic cancer in a number of tumour types – after the anti-angiogenic agent failed in its second Phase III trial in early-stage colon cancer to reduce the risk of disease recurrence. Meanwhile, the FDA has delayed its much-anticipated decision on Avastin's use in metastatic breast cancer after the company submitted new information.

Roche is facing further disappointment with its top selling drug, Avastin (bevacizumab) – which is so far approved for advanced/metastatic cancer in a number of tumour types – after the anti-angiogenic agent failed in its second Phase III trial in early-stage colon cancer to reduce the risk of disease recurrence. Meanwhile, the FDA has delayed its much-anticipated decision on Avastin's use in metastatic breast cancer after the company submitted new information.

The failure of Avastin to improve disease-free survival (DFS) in early-stage colon cancer in the Roche-sponsored AVANT trial looks likely...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Kymera Inks CDK2 Deal With Gilead

 

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

More from Therapeutic Category

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By 

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.